An updated synthesis of [11C]carfentanil for positron emission tomography (PET) imaging of the μ-opioid receptor

被引:16
|
作者
Blecha, Joseph E. [1 ]
Henderson, Bradford D. [2 ]
Hockley, Brian G. [2 ]
VanBrocklin, Henry F. [1 ]
Zubieta, Jon-Kar [3 ]
DaSilva, Alexandre F. [4 ]
Kilbourn, Michael R. [2 ]
Koeppe, Robert A. [2 ]
Scott, Peter J. H. [2 ]
Shao, Xia [2 ]
机构
[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA
[2] Univ Michigan, Dept Radiol, Med Sch, Ann Arbor, MI 48109 USA
[3] Univ Utah, Dept Psychiat, Univ Neuropsychiat Inst, Hlth Ctr, Salt Lake City, UT USA
[4] Univ Michigan, Sch Dent, Biol & Mat Sci Dept, Headache & Orofacial Pain Effort, Ann Arbor, MI 48109 USA
关键词
C-11; carbon-11; opioid; PET radiochemistry; radiosynthesis; MAJOR DEPRESSION; RESPONSES; NEUROTRANSMISSION; <C-11>CARFENTANIL; RADIOSYNTHESES; CHEMISTRY; BRAIN; WOMEN; PAIN;
D O I
10.1002/jlcr.3513
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
[C-11]Carfentanil ([C-11]CFN) is a selective radiotracer for in vivo positron emission tomography imaging studies of the -opioid system that, in our laboratories, is synthesized by methylation of the corresponding carboxylate precursor with [C-11]MeOTf, and purified using a C2 solid-phase extraction cartridge. Changes in the commercial availability of common C2 cartridges have necessitated future proofing the synthesis of [C-11]CFN to maintain reliable delivery of the radiotracer for clinical imaging studies. An updated synthesis of [C-11]CFN is reported that replaces a now obsolete purification cartridge with a new commercially available version and also substitutes the organic solvents used in traditional production methods with ethanol.
引用
收藏
页码:375 / 380
页数:6
相关论文
共 50 条
  • [31] [11C]carfentanil PET imaging for studying the peripheral opioid system in vivo: effect of photoperiod on mu-opioid receptor availability in brown adipose tissue
    Lihua Sun
    Richard Aarnio
    Erika Atencio Herre
    Salli Kärnä
    Senthil Palani
    Helena Virtanen
    Heidi Liljenbäck
    Jenni Virta
    Aake Honkaniemi
    Vesa Oikonen
    Chunlei Han
    Sanna Laurila
    Marco Bucci
    Semi Helin
    Emrah Yatkin
    Lauri Nummenmaa
    Pirjo Nuutila
    Jing Tang
    Anne Roivainen
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 266 - 274
  • [32] [11C]SSR180575, A PROMISING POSITRON EMISSION TOMOGRAPHY RADIOLIGAND FOR IMAGING THE PERIPHERAL BENZODIAZEPINE RECEPTOR
    Dolle, F.
    Boutin, H.
    Chauveau, F.
    Thominiaux, C.
    Van Camp, N.
    Roy, S.
    Boisnard, S.
    Rooney, T.
    Benavides, J.
    Hantraye, P.
    Boisgard, R.
    Tavitian, B.
    GLIA, 2009, 57 (13) : S137 - S137
  • [33] Dosimetry of 11C-carfentanil, a μ-opioid receptor imaging agent
    Newberg, Andrew B.
    Ray, Riju
    Scheuermann, Joshua
    Wintering, Nancy
    Saffer, Janet
    Schmitz, Alexander
    Freifelder, Richard
    Karp, Joel
    Lerman, Caryn
    Divgi, Chaitanya
    NUCLEAR MEDICINE COMMUNICATIONS, 2009, 30 (04) : 314 - 318
  • [34] In vivo imaging of activated microglia with [11C]PK11195 positron emission tomography (PET) in ischemic stroke
    Gerhard, A
    Schwarz, J
    Elitok, E
    Ludolph, AC
    Reske, SN
    Cagnin, A
    Goerres, G
    Brooks, DJ
    Banati, RB
    NEUROLOGY, 2000, 54 (07) : A95 - A95
  • [35] Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts
    Memon, Ashfaque A.
    Jakobsen, Steen
    Dagnaes-Hansen, Frederik
    Sorensen, Boe S.
    Keiding, Susanne
    Nexo, Ebba
    CANCER RESEARCH, 2009, 69 (03) : 873 - 878
  • [36] Synthesis and assessment of [11C]acetylhomotaurine as an imaging agent for the study of the pharmacodynamic properties of acamprosate by positron emission tomography
    Courtyn, J
    Cornelissen, B
    Oltenfreiter, R
    Vandecapelle, M
    Slegers, G
    Strijckmans, K
    NUCLEAR MEDICINE AND BIOLOGY, 2004, 31 (05) : 649 - 654
  • [37] Measurement of central µ-opioid receptor binding in vivo with PET and [11C]carfentanil: a test–retest study in healthy subjects
    Jussi Hirvonen
    Sargo Aalto
    Nora Hagelberg
    Anu Maksimow
    Kimmo Ingman
    Vesa Oikonen
    Jussi Virkkala
    Kjell Någren
    Harry Scheinin
    European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36
  • [38] A feasibility study of [11C]choline for the molecular imaging of human breast cancer in vivo using positron emission tomography (PET).
    Kenny, L. M.
    Coombes, R. C.
    Al-Nahhas, A.
    Osman, S.
    Lowdell, C.
    Aboagye, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 31S - 31S
  • [39] Discovery of [11C]MK-6884: A positron emission tomography (PET) imaging agent for M4 PAM
    Tong, Ling
    Li, Wenping
    Gao, Xiaolei
    Lo, Michael
    Wai, Jenny
    Rudd, Michael
    Tellers, David
    Zeng, Zhizhen
    Miller, Patricia
    Salinas, Cristian
    Riffel, Kerry
    Haley, Hyking
    Purcell, Mona
    Holahan, Marie
    Bueters, Tjerk
    Uslaner, Jason
    Morrow, John
    Mazzola, Rob
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [40] Improved Synthesis of Delta Opioid Receptor (DOR) Radioligand, N1′-([11C]Methyl)Naltrindole ([11C]MeNTI) for Positron Emission Tomographic Studies
    Kaur, Tanpreet
    Shao, Xia
    Brooks, Allen
    Scott, Peter
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61